Chronic Myeloid Leukemia pp 27-35 | Cite as
CML Mouse Model Generated from Leukemia Stem Cells
- 1.3k Downloads
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disorder with a high number of well-differentiated neutrophils in peripheral blood and myeloid cells in bone marrow (BM). CML is derived from the hematopoietic stem cells (HSCs) with the Philadelphia chromosome (Ph+, t(9;22)-(q34;q11)), resulting in generating a fusion oncogene, BCR/ABL1. HSCs with Ph+ are defined as leukemia stem cells (LSCs), a subpopulation cell at the apex of hierarchies in leukemia cells and responsible for the disease continuous propagation. Several kinds of CML models have been developed to reveal the mechanism of CML pathogenesis and evaluate therapeutic drugs in the past three decades. Here, we describe the procedures to generate a CML mouse model by introducing BCR/ABL1 into Lin−Sca1+ cKit+ population cells purified from mouse bone marrow. In CML retroviral transduction/transplantation mouse models, this modified model can mimic CML pathogenesis on high fidelity.
Key words
Chronic myeloid leukemia (CML) Leukemia stem cells (LSCs) Mouse model BCR/ABL1 Retroviral transduction/transplantationReferences
- 1.Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138:819–830CrossRefPubMedGoogle Scholar
- 2.Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN (1978) Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J Clin Invest 62:815–823CrossRefPubMedPubMedCentralGoogle Scholar
- 3.O’Hare T, Zabriskie MS, Eiring AM, Deininger MW (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12:513–526CrossRefPubMedGoogle Scholar
- 4.Lane SW, Gilliland DG (2010) Leukemia stem cells. Semin Cancer Biol 20:71–76CrossRefPubMedGoogle Scholar
- 5.Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice. Proc Natl Acad Sci U S A 103:16870–16875CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer AL, Auewarakul C, Barnett MJ, Eaves CJ, Eaves AC (2005) Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19:435–441CrossRefPubMedGoogle Scholar
- 7.Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A 94:5320–5325CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P (2014) Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 123:3951–3962CrossRefPubMedGoogle Scholar
- 9.Van Etten RA (2001) Models of chronic myeloid leukemia. Curr Oncol Rep 3:228–237CrossRefPubMedGoogle Scholar
- 10.Ilaria RL Jr (2004) Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am 18:525–543, viiCrossRefPubMedGoogle Scholar